<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01934738</url>
  </required_header>
  <id_info>
    <org_study_id>B5261002</org_study_id>
    <nct_id>NCT01934738</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06273340 in Healthy Subjects of Two AgeGroups, Aged 18-55 Years (Group 1) and Aged 56-75 Years (Group 2)</brief_title>
  <official_title>A Phase 1, Double Blind (3rd Party Open) Randomized, Placebo Controlled, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Doses of PF-06273340 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate safety, toleration and time course of plasma
      concentration of multiple oral doses of PF-06273340 for 14 days in healthy subjects of two
      age groups, aged 18-55 years (Group 1) and aged 56-75 years (Group 2)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve from Time Zero to end of dosing interval (AUCtau)</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Group 1: Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1: Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1: Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1: Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06273340</intervention_name>
    <description>Tablets, 100 mg TID, 14 days</description>
    <arm_group_label>Group 1: Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets, TID, 14 days</description>
    <arm_group_label>Group 1: Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06273340</intervention_name>
    <description>Tablets, to be decided dose, TID or titration, 14 days</description>
    <arm_group_label>Group 1: Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets, TID or titration, 14 days</description>
    <arm_group_label>Group 1: Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06273340</intervention_name>
    <description>Tablets, to be decided dose, TID or titration, 14 days</description>
    <arm_group_label>Group 1: Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets, TID or titration, 14 days</description>
    <arm_group_label>Group 1: Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06273340</intervention_name>
    <description>Tablets, to be decided dose, TID or titration, 14 days</description>
    <arm_group_label>Group 2: Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets, TID or titration, 14 days</description>
    <arm_group_label>Group 2: Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06273340</intervention_name>
    <description>Tablets, to be decided dose, TID or titration, 14 days</description>
    <arm_group_label>Group 1: Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets, TID or titration, 14 days</description>
    <arm_group_label>Group 1: Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06273340</intervention_name>
    <description>Tablets, to be decided dose, TID or titration, 14 days</description>
    <arm_group_label>Group 2: Cohort 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets, TID or titration, 14 days</description>
    <arm_group_label>Group 2: Cohort 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For Group 1 specific: Healthy male and/or female subjects of non-childbearing
             potential between the ages of 18 and 55 years, inclusive (Healthy is defined as no
             clinically relevant abnormalities identified by a detailed medical history, full
             physical examination, including blood pressure and pulse rate measurement, 12-lead ECG
             and clinical laboratory tests).

          -  For Group 2 specific: Healthy male and/or female subjects of non-childbearing
             potential between the ages of 56 and 75 years, inclusive. Subjects must be in
             reasonably good health as determined by the investigator based on a detailed medical
             history, full physical examination (including blood pressure and pulse rate
             measurement), 12-lead ECG and clinical laboratory tests. Subjects with mild, chronic,
             stable disease (eg, osteoarthritis) may be enrolled if deemed medically prudent by the
             investigator. In order to ensure an age range relevant to the osteoarthritis (OA)
             population, at least 50% of the subjects enrolled in these cohorts must be 60 years of
             age and above at Screening.

          -  For Group 2 specific: Subjects taking daily prescription or non-prescription
             medications for management of acceptable chronic medical conditions must be on a
             stable dose of these, as defined by non change in dose for the 3 months prior to the
             first dose of study medication and no planned changes during the conduct of the study.

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at the time of dosing).

          -  Any condition possibly affecting drug absorption (eg, gastrectomy).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Brussels</city>
        <zip>B-1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B5261002&amp;StudyName=A%20Study%20to%20Evaluate%20Safety%2C%20Toleration%20and%20Time%20Course%20of%20Plasma%20Concentration%20of%20Multiple%20Oral%20Doses%20of%20PF-06273340%20in%20Healthy%20Subj</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2013</study_first_submitted>
  <study_first_submitted_qc>August 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2013</study_first_posted>
  <last_update_submitted>March 9, 2014</last_update_submitted>
  <last_update_submitted_qc>March 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple dose</keyword>
  <keyword>safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>PK</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

